Integra LifeSciences | IART - Cash And Equivalent


Integra LifeSciences reported $235.05M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Abbott USD 8.52B 1.01B Dec/2025
AtriCure USD 167.43M 19.56M Dec/2025
Baxter International USD 1.97B 240M Dec/2025
Becton, Dickinson and Co. USD 740M 99M Dec/2025
Boston Scientific USD 1.96B 690M Dec/2025
CONMED USD 38.93M 4.99M Sep/2025
Cooper Companies USD 110.6M 14.3M Sep/2025
Dexcom USD 917.7M 918M Dec/2025
Edwards Lifesciences USD 2.69B 587.2M Sep/2025
Globus Medical USD 526.16M 154.39M Dec/2025
HeartBeam USD 4.38M 2M Dec/2025
Hologic USD 2.17B 208.5M Dec/2025
Insulet USD 716.1M 41.3M Dec/2025
Integra LifeSciences USD 235.05M 2.86M Dec/2025
Intuitive Surgical USD 9.03B 601.6M Dec/2025
J&J USD 19.71B 1.48B Dec/2025
Medtronic USD 1.15B 135M Dec/2025
Merit Medical Systems USD 446.4M 53.95M Dec/2025
Orthofix International USD 82.02M 19.16M Dec/2025
Stryker USD 4.01B 755M Dec/2025
Tandem Diabetes Care USD 90.63M 1.31M Dec/2025
Teleflex USD 354M 100.3M Sep/2025
Zimmer Biomet Holdings USD 591.9M 700.8M Dec/2025